We have studied a total of 188 patients with hematological malignancies, submitted to mobilization therapy with G-CSF associated or not with chemotherapy in order to: (1) establish the lower limit of circulating progenitor cells that allows the collection of 2 × 10 6 CD34 ؉ cells/kg by a single leukapheresis, utilizing the instrument set on standard parameters; (2) evaluate whether the number and quality of CD34 ؉ cells collected remain stable during leukapheresis; and (3) collect a sufficient number of circulating CD34
PBSC collection may be performed on an outpatient basis, the technology is widely available and safe, and it eliminates the need for hospitalization and general anesthesia. The very few circulating stem cells in normal peripheral blood or in the blood of patients with hematologic malignancies or solid tumors can be increased by the use of chemotherapy combined with G-CSF and different protocols have been successfully used to mobilize progenitor cells for transplantation. [3] [4] [5] [6] Several conditions, however, may hamper the collection of enough CD34 ϩ cells: relapsed or advanced disease, repeated courses of high-dose chemotherapy or hypocellular bone marrow can cause a poor CD34 ϩ cell mobilization and the need for repeated leukapheresis or even for several mobilization protocols. Although collections can be performed on consecutive days for patients who do not reach the target after the first collection, this may be prohibitive in some cases because of poor clinical condition, the fast decrease of progenitor cells in the blood and the high costs. The possibility of performing 'large volume leukapheresis' in an attempt to reduce the number of procedures has already been demonstrated; [7] [8] [9] however, the volume of the blood to be processed or the total time of the procedure was empirically set, resulting in the collection of either a large excess, or a still insufficient number of CD34 ϩ cells to procure bone marrow engraftment.
In this study, we analyzed the content of CD34 ϩ cells in the peripheral blood and in the leukapheresis products of 85 patients with hematologic malignancies and 147 procedures respectively, to define the cut-off of circulating CD34 ϩ cells that discriminates patients with a significant probability of collecting a sufficient number of progenitor cells by a single leukapheresis from those that need more than one procedure. Seventy subsequent patients were evaluated to confirm in a prospective study the identified cut-off value and to establish the number and quality of CD34 ϩ cells collected at different times during the procedure in order to define their stability both in the blood of the patients and in the layer formed in the instrument. Finally, in 33 patients the duration of the leukapheresis was adapted to each patient in an attempt to improve the efficacy of the procedure in patients with a low number of circulating CD34 ϩ cells. 
Patients and methods

Patient population
The study group includes 188 patients with hematological malignancies admitted to 269 stem cell collections by leukapheresis in the period between January 1996 and June 1998. The clinical characteristics are indicated in Table 1 . All patients were treated with mobilization protocols including G-CSF Ϯ chemotherapy; leukaphereses were started as soon as Ͼ1000 WBC/l and Ͼ10 CD34 ϩ cells/l were reached. Of the 188 patients, 85 (group 1) consecutively observed between January 1996 and February 1997 were included in the retrospective analysis to establish the lower limit of circulating CD34 ϩ cells/l that could allow the collection of progenitor cells by a single procedure; 70 patients (group 2) were prospectively evaluated to confirm that the cut-off value identified by the retrospective analysis could effectively discriminate patients in whom the target CD34 ϩ cell number could be collected with a single leukapheresis; 10 of the last 70 patients were also serially studied before leukapheresis, after 60 min, 120 min and at the end of the procedure to evaluate whether the number of CD34 ϩ cells/l, the distribution of different CD34 ϩ cell subpopulations and the clonogenic growth capacity remain stable during leukapheresis. Finally, 33 patients (group 3) with a number of circulating progenitor cells lower than the cut-off provided by the analysis of the 85 patients were evaluated to verify the possibility of collecting in a single apheresis the target cell number, by enumerating the collected CD34 ϩ cells 40-50 min prior to the completion of the leukapheresis and by estimating the blood volume that still needs to be processed. The majority of patients had non-Hodgkin's lymphoma (NHL) or multiple myeloma (MM); the other malignancies were acute leukemia (AL), chronic lymphocytic leukemia (CLL), Hodgkin's disease (HD) and myelodysplastic syndrome (MDS). At the time of the first collection, the median number of WBC/l was 4500 (range 1000-81 000), 6400 (range 2000-43 200) and 6700 (range 2500-73 000) for groups 1, 2 and 3, respectively. The median number of CD34 ϩ cells/l was 32 (range 10-1122), 41.6 (range 10-285) and 16 (range 10-19) for the three groups of patients, respectively. All patients had a subclavian vein single-or double-lumen catheter placed prior to leukapheresis which was utilized only to return processed blood because of the frequent luminal collapses observed when the catheter was used to draw blood. Largebore peripheral venous needles were inserted in all patients. The study was approved by the local ethical review board; informed consent was obtained from patients included in the prospective and experimental studies (groups 2 and 3).
Leukapheresis procedure
The COBE Spectra (COBE BCT Laboratories, Lakewood, CO, USA) was used for all the procedures. The patient's total blood volume was calculated by the instument according to weight, height and sex. The whole blood flow rate was set at 50-90 ml per min; the collecting pump was set at 1.0 ml per min, with the exception of two cases in which the pump was set at 1.5 ml/min in the last 60 min of the procedure. Anticoagulation was accomplished with ACD-A at a ratio of 12:1 blood:ACD-A for the first 500 ml and with 3000 units of heparin added to 500 ml of ACD-A at a ratio of 24:1 for the following quantities. Collections were started after G-CSF administration for at least 3 days, when WBC counts were greater than 1.0 × 10 9 /l and CD34 ϩ cells Ͼ10/l. In group 3 patients, the collected bag was evaluated both for the number of total nucleated cells and for the total CD34 ϩ cells 40 to 50 min prior to the completion of the procedure (set by the instrument at 2.5-fold the total patient's blood volume, calculated after deducting the ACD-A volume). The procedure was then continued for a period of time estimated to be sufficient to collect the target number of CD34 ϩ cells.
Analysis of CD34
ϩ cells by flow cytometry CD34 ϩ cells were enumerated in unseparated peripheral blood or in the collected bag during leukapheresis and at the end of the procedure, by incubating 3 × 10 5 cells with a FITC-conjugated anti-CD34 (HPCA-2; Becton Dickinson, San José, CA, USA) monoclonal antibody (MoAb) according to published methods. 10 Isotype and fluorochrome-matched irrelevant MoAbs (BD) were used as controls. For the three-color analysis performed in 10 patients of group 2, cells were incubated with the FITC-conjugated anti-CD34, PE-conjugated anti-CD13 (My-7; Coulter, Miami, FL, USA), PerCP-conjugated anti-HLA-DR (BD) MoAbs, either alone (to set compensation and detector levels) or combined. After incubation, cells were washed twice in PBS-NaN 3 and residual red cells were lysed with isomolar NH 4 
Short-term and long-term cultures of hemopoietic progenitors
In 10 patients of group 2, 1 × 10 5 mononuclear cells taken from the peripheral blood before leukapheresis, after 60 and 120 min and at the completion of the procedure, as well as directly from the sterile set of the instrument after 60, 120 min and at the completion of the procedure were plated in 35 mm Petri dishes in a volume of 1 ml Iscove's modified Dulbecco's medium (IMDM; GIBCO BRL Life Technologies, Grand Island, NY, USA) supplemented with fetal calf serum (30%) (Hyclone, Oud-Beijerland, The Netherlands), methylcellulose (1.2%) (Sigma, St Louis, MO, USA), 2-mercaptoethanol (5 × 10 −5 mol/l), l-glutamine (2 mm), penicillin (0.5 U/ml), streptomycin (0.5 g/ml), IL-3 (20 ng/ml) (Sandoz Pharma, Basel, Switzerland), GM-CSF (5 ng/ml) (Sandoz Pharma) and erythropoietin (5 IU/ml) (Eprex, Epoetine alpha, Cilag, Switzerland), according to established criteria.
11 After 10-14 days of incubation at 37°C and 5% CO 2 in air, granulocyte-macrophage colony-forming units (CFU-GM), erythroid burst-forming units (BFU-E) and mixed granuloerythropoietic colony-forming units (CFU-Mix) were counted using an inverted microscope. In three patients, longterm culture initiating cells (LTC-IC) were enumerated in mobilized peripheral blood before and at the end of leukapheresis, from the sterile set after 60 min and at the completion of the procedure, according to published methods. 12 Briefly, 5 × 10 5 mononuclear cells were plated by limiting dilution in contact with irradiated stromal layers of M2-10B4 cells, kindly provided by Dr C Eaves (Vancouver, BC, Canada) and maintained for 5 weeks at 37°C and 5% CO 2 , removing weekly half of the supernatant and replacing it with fresh LTC medium. After 5 weeks, all media were removed and the feeders overlaid with methylcellulose supplemented with EPO (3 IU/ml) and 10% supernatant of the 5637 cell line. The absolute number of LTC-IC was calculated using Poissons' statistics.
Evaluation of engraftment ability of the collected CD34 ϩ cells
In all patients submitted to the autograft, PB and marrow samples were taken at regular intervals after autograft. Hematologic recovery was defined as the number of days necessary to reach 0.5 × 10 
Statistical analysis
Linear regression was used to correlate the number of circulating CD34 ϩ cells/l, WBC/l, mononuclear cells/l and platelets/l with the number of CD34 ϩ cells collected. The number of CD34 ϩ cells with the highest probability of defining the two groups of patients submitted to one or more than one leukapheresis to collect the target of 2 × 10 6 CD34 ϩ cells/kg was calculated on the basis of the relationship between sensitivity, specificity and the cut-off through the 'receiver operating characteristic' curve (ROC). 13, 14 Friedman's test was used for comparison of multiple in vitro tests in the same individuals. The results of the prospective study evaluating patients with Ͻ19 CD34 ϩ cells/l and those with Ͼ19 CD34 ϩ cells/l were analyzed by the Mann-Whitney rank sum test. The time to engraftment of the four groups of patients with different numbers of CD34 ϩ cells reinfused, or different ability to mobilize CD34 ϩ cells was compared by the KruskalWallis test.
Results
The absolute number of circulating CD34
ϩ cells may predict the number of CD34 ϩ cells collected and the number of leukapheresis to be performed
In preliminary experiments, we correlated the number of circulating CD34 ϩ cells/l, WBC/l, mononuclear cells/l and platelets/l present in the blood of patients before starting the procedures with the number of CD34 ϩ cells col- In order to define the cut-off number of circulating CD34 ϩ cells which may discriminate between patients who will require one or more aphereses to collect the target number of progenitor cells, we have analyzed the relationship between sensitivity, specificity and cut-off by the ROC curve. Figure 1 reports the curve plotted for various CD34 ϩ cell numbers which represents the true positive rate (sensitivity of the test) vs the false positive rate (specificity of the test). Points representing equal values of X and Y axes will be located on the dotted diagonal (chance line), representing a ROC curve of a test with no significative value, unable, therefore, to discriminate between a true and false positive rate. The slope of the ROC curve plotted with the 85 patients of group 1 demonstrated a high accuracy of the test (area index = 0.9831) and 19 was the number of Table 3 Stability of hemopoietic progenitors at different times during leukapheresis in samples taken both from the blood and from the sterile set of the instrument ϩ cells/kg were significantly different between the two groups ( Table 2) .
Concentration of early progenitors and more committed cells before leukapheresis and at different times during the procedure
In 10 of the 70 patients of group 2, the number of early progenitors (LTC-IC, CFU-GEMM) and of more differentiated cells (CFU-GM, BFU-E), as well as the number of CD34 ϩ cells and of some CD34 ϩ cell subpopulations were evaluated in samples taken from PB and directly from the sterile set of the instrument at different times during leukapheresis. As reported in Table 3 , no differences were found in any of the progenitor cell types considered; their stability in the PB and the steady recovery through the instrument provided the rationale for the subsequent part of the study.
Parameters set at the starting of leukapheresis
Thirty-three patients (group 3) eligible for PBSC collection with a number of circulating CD34 ϩ cells Ͼ10/l and Ͻ19/l were studied. According to height, weight, sex and hematocrit, the instrument automatically adjusted the volume of blood to be processed and the other parameters to be followed during stem cell collection to process 2.5 times the total blood volume (after deducting ACD-A volume) of each of the 33 patients. The median total volume to be processed was 12 260 ml (range 7990-15 910) and the median volume to be collected was 222 ml (range 175-275), with the collect pump running at 1.0 ml/min in all cases. Table 4 reports the number of CD34 ϩ cells/l in the blood before starting leukapheresis and in the collected bag 40 to 50 min prior to completing the procedure (intermediate control), together with the total CD34 ϩ cells/kg collected at this time and the estimated minimum blood volume to be processed to reach the target of 2 × 10 6 CD34 ϩ cells/kg. Before starting leukapheresis, the median number of /kg; however, while in 29 patients the estimated blood volume to be processed to reach the target number of CD34 ϩ cells exceeded that indicated by the instrument before the start of the leukapheresis, in four cases the collection of CD34
CD34 ϩ cells in the blood and at the intermediate control in the collected bag
ϩ cells was such that the estimated blood volume to be processed was smaller than that planned (patients 4, 8, 9, 19 ). The overall total median blood volume estimated to be processed was 14 500 ml (range 7200-22 200), compared to 12 260 ml (range 7990-15 910) set by the instrument at the start of the procedure.
Effectiveness of the predicted values to collect the target number of CD34 ϩ cells
Several values obtained at the end of the procedures are indicated in Table 4 . A median of 16 201 ml (range 9900-22 200) of blood was processed; the difference between the predicted and the processed volume was due to the attempt to increase the number of CD34 ϩ cells collected in patients for whom the duration of the procedure was not excessive (Ͻ20 000 ml processed) and devoid of major discomfort. The median increment calculated from the volume set automatically by the instrument was 25.2% (range 0-135.6), with a median of 3.3-fold (range 2.5-5.9) total blood volume processed. The maximum duration time of the procedure was 351 min; in all cases, the procedure was well tolerated with no major side-effects due to anticoagulation or hypotension. In all cases, the CD34 ϩ cell collection was completed in a single procedure. The concentration of CD34 ϩ cells/l in the collection bag was similar to the CD34 ϩ cell concentration at the intermediate control (Ϯ10% variation) in 16 cases, higher in 15 and lower in two. Overall, there were no significant differences between the two controls.
Ability of CD34 ϩ cells to reconstitute patients after autograft
All patients entered in the study were part of clinical protocols which included the autograft as part of their therapeutic program. The conditioning regimens utilized to treat patients before reinfusion of PBSC varied according to diagnosis or to the study protocol. In general, patients with NHL were submitted to the BEAC protocol, 15 patients with HD or CLL to the BEAM regimen, 16 while AL and MDS received busulphan and cyclophosphamide. 17 Patients with MM received busulphan and melphalan at standard dosages 18 with or without idarubicin at 42 mg/m 2 given by continuous infusion for 2 days. The majority of patients were not treated with growth factors to accelerate recovery after autograft; however, patients with CLL and those with MM treated with idarubicin, busulphan and melphalan received G-CSF at 5 g/kg after the reinfusion of PBSC.
To evaluate whether patients submitted to prolonged stem cell collection would afford a delayed engraftment of PMN and PLT after autograft, and whether the time to engraftment could be influenced by the stem cell mobilization ability or the number of CD34 ϩ cells reinfused, we compared the number of days to reach 0.5 × 10 9 /l PMN and 50 × 10 9 /l PLT in four groups of patients (groups A-D), as described in Patients and methods. Overall, data for PB reconstitution were available in all the 82 autografted patients, since no failure to engraft was observed. The short follow-up after reinfusion, the high number of patients still in the waiting list for an autograft, relapse between stem cell collection and autograft, poor clinical condition at the time of transplant, or patients' refusal were the major causes accounting for the differences between the number of patients studied and the number of patients autografted. Table 5 shows the time (days) to reach 0.5 × 10 9 /l PMN and 50 × 10 9 /l PLT after stem cell reinfusion in the four groups of patients, compared by the Kruskall-Wallis test. There was no difference in the number of days to reach 0.5 × 10 9 /l PMN between the four groups; however, a significantly shorter time to reach 50 × 10 9 /l PLT (P Ͻ 0.001) was observed for patients receiving Ͼ4 × 10 6 CD34 ϩ cells/kg. The group of patients monitored during apheresis in order to collect 2 × 10 6 CD34 ϩ cells/kg by prolonging the duration of the procedure, showed similar engraftment kinetics both of PMN and PLT, compared to the other groups of patients who received a comparable number of CD34 ϩ cells.
Discussion
PBSC are increasingly used as a source of stem cells for transplantation both in the autologous and in the allogenic setting. In patients with hematologic malignancies, a good mobilization of CD34 ϩ cells is usually achieved through the use of cyclophosphamide or other cytotoxic drugs and G-CSF. 19, 20 However, in patients with advanced disease, the use of drugs with marked bone marrow toxicity or the previous administration of repeated cycles of chemotherapy Ϯ radiotherapy during the course of the disease may be limiting factors for the collection of a sufficient number of blood CD34
ϩ cells or repeated leukapheresis may be required to reach the minimum target of CD34 ϩ cells. [21] [22] [23] The lowest number of stem cells that allows a long-term engraftment in ablated recipients is not defined. 24 Although several reports have shown benefit for receiving doses of CD34 ϩ cells greater than 10 × 10 6 /kg, such a number is not easily attainable in the majority of patients with hematologic malignancies. 25, 26 In general, 2 × 10 6 CD34 ϩ cells/kg are considered sufficient to produce engraftment and reconstitution after autograft. 27 Several studies have addressed the issue of the lowest number of circulating CD34 ϩ cells/l sufficient to admit patients to leukapheresis. 27, 28 Despite the controversies on this point, less than 8-10 CD34 ϩ cells/l is considered too low to produce a valid leukapheresis and to reach the target in an acceptable number of procedures. 29 Very few studies have, however, evaluated the cut-off number of circulating CD34 ϩ cells that would discriminate between one and more than one procedure to collect 2 × 10 6 CD34 ϩ cells/kg. In this study, we explored the possibility of reaching the target of 2 × 10 6 CD34 ϩ cells/kg in a single leukapheresis in patients with a poor stem cell mobilization through the close monitoring of CD34 ϩ cells during the procedure and the processing of a large blood volume if needed. The two requirements were that the concentration of CD34 ϩ cells in the blood did not vary significantly during the leukapheresis and that stem cell recovery through the instrument would remain stable during the procedure. Evaluation of CD34 ϩ cells present in the collection bag 1 h before the completion of the procedure would allow estimation of the total duration of the leukapheresis. Obviously, only patients with a low number of circulating stem cells could be admitted to the study because of the large number of CD34 ϩ cells that can be collected in well mobilized cases. To admit patients that would probably need more than one leukapheresis to reach the target with the instrument set on standard parameters, we have calculated the lowest number of circulating CD34 ϩ cells that would allow the collection of 2 × 10 6 CD34 ϩ cells in a single procedure. Eighty-five patients, with a range of circulating CD34 ϩ cells between 10 and 559/l, were analyzed using the relationship between sensitivity, specificity and cut-off by the ROC curve. 13, 14 The analysis showed that patients having Ͼ19 circulating CD34 ϩ cells/l have a significant probability of collecting the target CD34 ϩ cell number in a single procedure, while those with Ͻ19 CD34 ϩ cells/l need more than one procedure. A further 70 patients provided confirmation, in a prospective analysis, that the value of 19/l could effectively discriminate between patients admitted to one apheresis or more; this held true for 69/70 patients, including, therefore, all body weight ranges and for a blood volume processed ranging between 8000 and 16 000 ml, as well as for the 16 patients clustered around the critical value of 19 CD34 ϩ cells/l (15-25/l), for whom the possibility of failing the appropriate collection was more likely. The only patient who failed to yield the target CD34 ϩ cell dose in a single apheresis had 20 CD34 ϩ cells/l in the PB, but an inadequate vein access to allow stable buffy coat layer formation during the procedure.
Attempts to reduce the number of leukaphereses have been explored through the use of 'large volume collection' that have demonstrated the feasibility of 4-5 h procedures with good recovery of CD34 ϩ cells and no major sideeffects due to the anticoagulation or to the volume of blood processed. The large volume collection, however, may result either in an excess of CD34 ϩ cells collected, or in a still insufficient number that necessarily leads to repeating the procedure the following day. This event, in our experience, is stressful for the patient, time-consuming and expensive. Through the evaluation of CD34 ϩ cells in the collection bag 50-60 min prior to completing the procedure, we could easily calculate the residual time (or residual blood volume) required to complete an adequate stem cell collection. In all 33 patients studied, a single procedure was sufficient to reach the CD34 ϩ cell target with no greater discomfort for the patients. The blood volume processed was increased by a median of 25.2% (range 0-135.6) compared to the volume processed in the standard procedure, the longest leukapheresis being of 351 min. The median number of CD34 ϩ cells × 10 6 /kg collected was 2.4 (range 2.1-4.6). Finally, we evaluated whether the prolonged duration of the procedure or the CD34 ϩ cells collected from patients with a poor mobilization capacity could represent a disadvantage in engraftment potential and in the time to peripheral blood reconstitution after autograft. Four groups of patients were evaluated, according to their circulating CD34 ϩ cells, the number of procedures performed and the number of CD34 ϩ cells reinfused. No difference was found in the time to PMN and PLT reconstitution between the group of patients admitted to the prolonged procedure (group A) and the other groups of patients who received a comparable number of CD34 ϩ cells. However, patients who were reinfused with Ͼ4 × 10 6 CD34 ϩ cells/kg (group D), collected from PB containing a median of 74 CD34 ϩ cells/l (range 24-1122), showed a faster PLT reconstitution compared to the other groups. The similar pattern of PMN reconstitution observed between the four groups demonstrated that the target of CD34 ϩ cells used in our study (2 × 10 6 /kg) is probably excessive in terms of long-term BM engraftment and a complete PB reconstitution; further studies are needed to establish whether lower numbers of CD34 ϩ cells reinfused may still allow comparable PMN and PLT reconstitution.
The strategy of stem cell collection used in the present study was feasible and well tolerated, even for the seven patients in whom more than 20 liters of blood were processed. Certainly, longer procedures would have allowed larger stem cell collections, although the maximum duration of a safe leukapheresis still needs to be better defined.
The reduction in cost of the procedures is the other major advantage of our collection strategy. Comparisons between the short-term medical costs for patients transplanted with steady-state blood and G-CSF mobilized blood, or comparisons between the costs of mobilized blood cells and BM transplants have already been reported. 30, 31 Certainly, the total global cost of a transplant procedure must take into account the quality of life, the duration of therapy and several other parameters, which are not easy to determine. However, in the group of 33 patients selected for the low number of circulating CD34 ϩ cells, 90% would have completed stem cell collection in more than one leukapheresis, should the latter have been performed with the instrument set on standard parameters. This would have resulted in the use of an excess of sterile sets and anticoagulant, in addition to more cryopreservation and growth factor costs.
Certainly, stem cell collection through leukapheresis is still to be fully optimized. The use of newer automated machines and of sophisticated software will improve the output of the instrument, while the use of more appropriate strategies of mobilization regimens, CD34 ϩ cell evaluation and the optimization of the timing and duration of the procedure will improve the therapeutic effect of PBSC autograft.
